Bing Lin, Ph.D., CEO
Dr. Bing Lin joined Zensun USA in 2012 as Director of CMC. He has more than 14-year industrial experience in biotechnology and pharmaceutical companies on protein science and CMC. Before joining Zensun USA, he served as Director of Protein Chemistry in Anaphore and leaded a team for protein production, purification, characterization and CMC. Prior to that, he held lead positions in Novartis GNF as Investigator II and in Alexion Pharmaceuticals as Senior Scientist. Dr. Lin earned his Ph.D. from Kansas State University and the Certificate for Regulatory Affairs Essentials from University of California at San Diego. Since October 2016, Dr. Lin began to take the responsibility as CEO of Zensun USA.
Lei Zhang, Ph.D. VP of Global Clinical Development & Operations
Dr. Zhang serves as VP of Global Clinical Development & Operations at Zensun USA overseeing global clinical studies. Dr. Lei Zhang has over 15 years of experience in clinical & medical affairs that span across the medical device, biotechnology, and diagnostic industries. Prior to Zensun, Dr. Zhang held management positions in Clinical & Medical Affairs and R & D at Alere, Cytori Therapeutics, Inovio Biomedical, Halozyme Therapeutics and Genetronics, Inc. Dr. Zhang earned her Ph.D. in Biophysics from Friedrich-Shiller Univ. in Germany.
Kate Vilaychack-Rizzo, Global Executive Director of Quality Assurance/ Regulatory Affairs
Kate received her Bachelor degree in Chemistry from the University of Illinois at Chicago and the Regulatory Affairs Certification from San Diego State University and is licensed with the Board of Pharmacy across the United States. Kate has more than 15 years of experience in the pharmaceutical and Medical Device industries, and she joined Zensun USA, Inc. in 2014, to lead the Quality Assurance/Regulatory Affairs departments within the USA and China.